PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer
Authors:
Open Access
- 30 April 2024
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 43 (5) , 114176
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- NCI (T32CA009686, P30CA051008, R21CA258153, F31CA247417)
This publication has 75 references indexed in Scilit:
- KIF11 manipulates SREBP2‐dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinomaCancer Medicine, 2022
- Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patientsCancer Chemotherapy and Pharmacology, 2020
- Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossCancer Cell, 2019
- A Potent, Selective and Cell‐Active Allosteric Inhibitor of Protein Arginine Methyltransferase 3 (PRMT3)Angewandte Chemie International Edition, 2015
- SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolismTumor Biology, 2015
- Organoid Models of Human and Mouse Ductal Pancreatic CancerCell, 2015
- Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1Bioorganic & Medicinal Chemistry, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humansCellular and Molecular Life Sciences, 2009
- FCM: The fuzzy c-means clustering algorithmComputers & Geosciences, 1984